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Abstract Research Question 
Literature Review 
Discussion 
 In both the MATTERs and CRASH-2 studies, TXA improved 
survival.  
 A slight increase in thromboembolic events was noted in the TXA 
group during the MATTER study. However, this could be 
explained by the TXA group being the more severely injured. 
 In the Israel Defense Forces’ Initial Experience study and the other 
pre-hospital studies that implemented TXA, no adverse effects 
were noted. However, the sample sizes were relatively small. 
 1 patient treated with TXA out of 67 benefited (nnt=67) from 
treatment. 
 Future studies should strive for more objective inclusion and 
exclusion criteria while using larger sample populations and 
objective measurement techniques.  
  There are current studies in progress that will further address any 
shortcomings: The STAAMP (Study of Tranexamic acid during air 
medical prehospital transport trial) and the PATCH (Pre-hospital 
Antifibrinolytics for Traumatic Coagulopathy and Hemorrhage) 
Study.  
 
 
   
 Nearly 40% of deaths after trauma can be attributed to blood loss. It is 
well known that early surgical interventions, combined with other 
treatment modalities found in the hospital setting, lead to the decreased 
morbidity and mortality of trauma patients. However, in an outpatient 
setting, treatments for hemorrhage control are extremely limited.  
 The purpose of this literature review was to explore tranexamic acid 
(TXA) use as an option for hemorrhage control and to determine its effect 
on morbidity and mortality in both prehospital and outpatient settings.  
TXA is an FDA approved antifibrinolytic that has proven efficacy for 
hemorrhage control during many types of surgery and for conditions such 
as heavy menstrual bleeding. TXA acts on the normal processes of the 
body’s clotting cascade and promotes clotting, while preventing clot 
breakdown.  
 Data supporting the use of TXA in settings outside of the hospital has 
previously been limited. This literature review explored recently 
conducted studies that demonstrate the effects on morbidity and mortality 
of patients treated with TXA in setting outside of a hospital.   
 Evidence from information gathered further promoted the use of TXA in 
settings such as, EMS, battlefield medicine, and rural health care facilities 
in certain types of trauma. TXA administration reduced the morbidity and 
number of deaths from blood loss in the aforementioned settings.  
 The findings advocate for the addition of TXA into trauma protocols 
shows it will lead to a decrease in the number of deaths due to blood loss 
in trauma. 
 
 What are the effects on morbidity and mortality of 
Tranexamic Acid on trauma patients in the 
prehospital setting? 
 The benefits of TXA on preventing death from hemorrhage, depends 
on the time between the injury and the start of treatment. Clearly, the 
earlier the treatment is initiated, the better the results (Shakur et al., 
2010). Trauma patients presenting to small town emergency rooms, 
clinics, rural health facilities, can now be offered a medicine that has 
the potential to save their life when it otherwise may not have been 
possible.  
 The World Health Organization has added TXA to list of essential 
medications (Ker et al., 2012). Subsequently, many hospitals, EMS 
and air ambulance services, and military health care providers have 
already begun to implement TXA into their prehospital trauma 
protocols. In fact, the Military has designated the use of TXA a Class I 
recommendation in the Tactical Combat Casualty Care guidelines.  
Major EMS organizations, such as Hennepin County EMS (HEMS) 
have developed and are using current TXA protocols. Additionally, the 
International Trauma Life Support has expressed its consent towards 
the implementation of prehospital TXA protocols (Copeland et al., 
2011).  
 With the studies reviewed here it is clear to see that the prehospital use 
of TXA in trauma is a safe and effective addition to any current trauma 
protocol. Not every trauma patient benefits from TXA and there are 
limitations to its use. However, with appropriate training and careful 
review of the current supporting literature, healthcare providers can 
make an informed medical decision on a medicine that has the 
potential to save a life. 
 To the faculty of the UND Physician Assistant Program for the 
tireless work put in to our education. 
 To my wife and family for their support.   
Introduction 
 Tranexamic acid is a medication that has been used in hospital settings for over 
40 years.  It is an antifibrinolytic, which currently, is being used most 
frequently to treat postpartum hemorrhage, heavy menstrual bleeding, and peri-
operatively for surgical procedures. It is widely used in over-the-counter 
settings and in hospitals due to it’s safety, efficacy, and inexpensive nature. 
However, use in prehospital and trauma settings has been scarcely documented 
until recently and has yet to be FDA approved for use in trauma.  
 To mediate this lack of research and to allow providers to make informed and 
potentially life saving decisions, it is necessary to examine all obtainable 
evidence. 
 When existing research is compiled and analyzed, several important 
conclusions are clearly drawn, yet other questions remain. Mainly, TXA is 
shown to be beneficial in trauma patients who were admitted to a hospital, and 
TXA reduces mortality if given early (Shakur, Roberts, Bautista, Caballero, 
Coats…, 2010). Similarly, positive effects on the reduction of mortality in 
combat surgical hospitals in Afghanistan were shown when TXA was used 
(Morrison, Dubose, Rasmussen, & Midwinter, 2012). Conversely, TXA will 
actually increase mortality if given after a specific amount of time, and in one 
study higher incidences of both pulmonary embolism and cardiovascular 
embolism were shown (Roberts, Shakur, Coats, Hunt, Balogun, Barnetson, & 
Guerriero, 2013).   
 
Applicability to Clinical 
Practice 
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Mechanism of Action 
According to McCance and Huether (2010), when injury occurs and the 
endothelial cell surface is exposed, the internal and external hemostasis 
pathways become activated. The clotting cascade begins and in summary, 
the following occurs: platelets bind to the site of injury, fibrinogen and 
plasminogen become entrapped in the platelet plug, fibrinogen is cleaved is 
turned into the fibrin clot.  Eventually, plasminogen is cleaved into plasmin 
which breaks apart the clot. It is here where TXA exerts its effect. TXA 
competitively binds to receptors on fibrin that would otherwise bind to 
plasminogen. The result is less plasminogen in the clot and subsequently 
less plasmin to degrade the clot later. Plasmin acts as a key ingredient in 
clot breakdown by degrading fibrin resulting in a weaker clot.  
 
TXA for trauma 
 The Clinical Randomization of an Antifibrinolytic in Significant Hemorrhage-2 
(CRASH 2) study was conducted from 2005 to 2010 and, to date, has been the most 
comprehensive examination of the effects of TXA use in trauma patients (Shakur et 
al., 2010).  
274 hospitals from 40 countries provided the 20,211 participants for the 
randomized-placebo controlled study (Shakur et al., 2010). Each subject was an 
adult trauma patient with or at risk of significant bleeding, within 8 hours of injury.  
This study showed TXA is most beneficial with >30% reduction in all cause 
mortality; (p = 0.0035) if given in conjunction with blood transfusion and within 
one hour of injury. A greater than 20% reduction in mortality was noted with just 
TXA alone.  
 The Military Application of Tranexamic Acid in Trauma Emergency Resuscitation 
(MATTERs) Study (Morrison, Dubose, Rasmussen, & Midwinter, 2012) was a 
retrospective observational study comparing the administration of TXA to no TXA 
in patients with combat injuries and who were receiving at least one unit of blood 
(n=896). These patients and the data from the study came from a Role 3 Echelon 
surgical hospital in southern Afghanistan (similar to a level two trauma center in the 
U.S.).  
The MATTERs study found that patients who received TXA had a lower 
unadjusted mortality (17.4%) when compared to the no TXA group (23.9%; p=.03) 
even with the TXA group having been classified as more severely injured with a 
mean Injury Severity Score of 25.2 with a standard deviation of  16.6. The No TXA 
group had a mean Injury Severity Score of 22.5 with a standard deviation of 18.5; 
(p=<0.001).  
 
Pre-hospital use of TXA for trauma 
The Israel Defense Forces’ Initial Experience study (Lipsky, Abramovich, 
Nadler, Feinstein, Shaked, Kreiss, & Glassberg, 2014) explored the effects 
of TXA on all casualty soldiers treated with TXA between December 2011 
and February 2013 (n=40).  
Thirty-five of the casualties (88%) were male, with a mean age of 28. In 
each case, 1 g of TXA was administered over 5-10 minutes intravenously, 
either by slow push or mixed with crystalloid. Thirty-three received their 
TXA within one hour of injury, while the remaining 7 received theirs 
within 2 hours, with the median of elapsed time between injury and 
injection of 46 minutes.  
Lipsky et al., (2014) concluded that without delaying evacuation, TXA 
was administered earlier than it would have been in the hospital, with no 
reports of adverse outcome when Glasgow Coma Scale scores, vitals, 
procedures performed, and life saving measures used, were compared. 
In a related study titled Prehospital Use of Tranexamic Acid for 
Hemorrhagic Shock in Primary and Secondary Air Medical Evacuation 
(Vu, Schlamp, Wand, Kleine-Deters, Vu, & Tallon, 2013), TXA was 
introduced into a Critical Care Paramedic (CCP) flight program.  
TXA was used by flight crews a total of 13 times in patients deemed to 
have experience major trauma as defined by the research parameters set in 
the BCAS Code 99 Trauma Triage Protocols. Indications for administration 
of TXA were based on age (at least 16 years or older), trauma, heart rate 
greater than 110 bmp, or systolic blood pressure less than 90 mm Hg (Vu et 
al., 2013).  
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